These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 33879555)

  • 21. Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance.
    Cretella D; Saccani F; Quaini F; Frati C; Lagrasta C; Bonelli M; Caffarra C; Cavazzoni A; Fumarola C; Galetti M; La Monica S; Ampollini L; Tiseo M; Ardizzoni A; Petronini PG; Alfieri RR
    Mol Cancer; 2014 Jun; 13():143. PubMed ID: 24898067
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110.
    Domínguez JM; Pérez-Chacón G; Guillén MJ; Muñoz-Alonso MJ; Somovilla-Crespo B; Cibrián D; Acosta-Iborra B; Adrados M; Muñoz-Calleja C; Cuevas C; Sánchez-Madrid F; Avilés P; Zapata JM
    J Hematol Oncol; 2020 Apr; 13(1):32. PubMed ID: 32264921
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MEN1309/OBT076, a First-In-Class Antibody-Drug Conjugate Targeting CD205 in Solid Tumors.
    Merlino G; Fiascarelli A; Bigioni M; Bressan A; Carrisi C; Bellarosa D; Salerno M; Bugianesi R; Manno R; Bernadó Morales C; Arribas J; Dusek RL; Ackroyd JE; Pham PH; Awdew R; Aud D; Trang M; Lynch CM; Terrett J; Wilson KE; Rohlff C; Manzini S; Pellacani A; Binaschi M
    Mol Cancer Ther; 2019 Sep; 18(9):1533-1543. PubMed ID: 31227646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-Lymphocyte Antigen 6 Complex, Locus E-
    Yip V; Figueroa I; Latifi B; Masih S; Ng C; Leipold D; Kamath A; Shen BQ
    Drug Metab Dispos; 2020 Dec; 48(12):1247-1256. PubMed ID: 33020064
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors.
    Gymnopoulos M; Betancourt O; Blot V; Fujita R; Galvan D; Lieuw V; Nguyen S; Snedden J; Stewart C; Villicana J; Wojciak J; Wong E; Pardo R; Patel N; D'Hooge F; Vijayakrishnan B; Barry C; Hartley JA; Howard PW; Newman R; Coronella J
    Mol Oncol; 2020 Jan; 14(1):54-68. PubMed ID: 31736230
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibody drug conjugates against the receptor for advanced glycation end products (RAGE), a novel therapeutic target in endometrial cancer.
    Healey GD; Pan-Castillo B; Garcia-Parra J; Davies J; Roberts S; Jones E; Dhar K; Nandanan S; Tofazzal N; Piggott L; Clarkson R; Seaton G; Frostell A; Fagge T; McKee C; Margarit L; Conlan RS; Gonzalez D
    J Immunother Cancer; 2019 Oct; 7(1):280. PubMed ID: 31665084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity.
    Ogitani Y; Hagihara K; Oitate M; Naito H; Agatsuma T
    Cancer Sci; 2016 Jul; 107(7):1039-46. PubMed ID: 27166974
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunoregulation by IL-7R-targeting antibody-drug conjugates: overcoming steroid-resistance in cancer and autoimmune disease.
    Yasunaga M; Manabe S; Matsumura Y
    Sci Rep; 2017 Sep; 7(1):10735. PubMed ID: 28878234
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trastuzumab-deBouganin Conjugate Overcomes Multiple Mechanisms of T-DM1 Drug Resistance.
    Dillon RL; Chooniedass S; Premsukh A; Adams GP; Entwistle J; MacDonald GC; Cizeau J
    J Immunother; 2016 Apr; 39(3):117-26. PubMed ID: 26938945
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates.
    Jackson D; Atkinson J; Guevara CI; Zhang C; Kery V; Moon SJ; Virata C; Yang P; Lowe C; Pinkstaff J; Cho H; Knudsen N; Manibusan A; Tian F; Sun Y; Lu Y; Sellers A; Jia XC; Joseph I; Anand B; Morrison K; Pereira DS; Stover D
    PLoS One; 2014; 9(1):e83865. PubMed ID: 24454709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression.
    Menderes G; Bonazzoli E; Bellone S; Black J; Predolini F; Pettinella F; Masserdotti A; Zammataro L; Altwerger G; Buza N; Hui P; Wong S; Litkouhi B; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
    Clin Cancer Res; 2017 Oct; 23(19):5836-5845. PubMed ID: 28679774
    [No Abstract]   [Full Text] [Related]  

  • 32. Development of a Novel Antibody-Drug Conjugate for the Potential Treatment of Ovarian, Lung, and Renal Cell Carcinoma Expressing TIM-1.
    Thomas LJ; Vitale L; O'Neill T; Dolnick RY; Wallace PK; Minderman H; Gergel LE; Forsberg EM; Boyer JM; Storey JR; Pilsmaker CD; Hammond RA; Widger J; Sundarapandiyan K; Crocker A; Marsh HC; Keler T
    Mol Cancer Ther; 2016 Dec; 15(12):2946-2954. PubMed ID: 27671527
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activating Autophagy Enhanced the Antitumor Effect of Antibody Drug Conjugates Rituximab-Monomethyl Auristatin E.
    Wang Y; Zhang X; Fan J; Chen W; Luan J; Nan Y; Wang S; Chen Q; Zhang Y; Wu Y; Ju D
    Front Immunol; 2018; 9():1799. PubMed ID: 30123222
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of attachment site on stability of cleavable antibody drug conjugates.
    Dorywalska M; Strop P; Melton-Witt JA; Hasa-Moreno A; Farias SE; Galindo Casas M; Delaria K; Lui V; Poulsen K; Loo C; Krimm S; Bolton G; Moine L; Dushin R; Tran TT; Liu SH; Rickert M; Foletti D; Shelton DL; Pons J; Rajpal A
    Bioconjug Chem; 2015 Apr; 26(4):650-9. PubMed ID: 25643134
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preclinical Antitumor Activity of a Novel Anti-c-KIT Antibody-Drug Conjugate against Mutant and Wild-type c-KIT-Positive Solid Tumors.
    Abrams T; Connor A; Fanton C; Cohen SB; Huber T; Miller K; Hong EE; Niu X; Kline J; Ison-Dugenny M; Harris S; Walker D; Krauser K; Galimi F; Wang Z; Ghoddusi M; Mansfield K; Lee-Hoeflich ST; Holash J; Pryer N; Kluwe W; Ettenberg SA; Sellers WR; Lees E; Kwon P; Abraham JA; Schleyer SC
    Clin Cancer Res; 2018 Sep; 24(17):4297-4308. PubMed ID: 29764854
    [No Abstract]   [Full Text] [Related]  

  • 36. The collagen receptor uPARAP/Endo180 as a novel target for antibody-drug conjugate mediated treatment of mesenchymal and leukemic cancers.
    Nielsen CF; van Putten SM; Lund IK; Melander MC; Nørregaard KS; Jürgensen HJ; Reckzeh K; Christensen KR; Ingvarsen SZ; Gårdsvoll H; Jensen KE; Hamerlik P; Engelholm LH; Behrendt N
    Oncotarget; 2017 Jul; 8(27):44605-44624. PubMed ID: 28574834
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SGN-LIV1A: a novel antibody-drug conjugate targeting LIV-1 for the treatment of metastatic breast cancer.
    Sussman D; Smith LM; Anderson ME; Duniho S; Hunter JH; Kostner H; Miyamoto JB; Nesterova A; Westendorf L; Van Epps HA; Whiting N; Benjamin DR
    Mol Cancer Ther; 2014 Dec; 13(12):2991-3000. PubMed ID: 25253783
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models.
    Vaisitti T; Arruga F; Vitale N; Lee TT; Ko M; Chadburn A; Braggio E; Di Napoli A; Iannello A; Allan JN; Miller LL; Lannutti BJ; Furman RR; Jessen KA; Deaglio S
    Blood; 2021 Jun; 137(24):3365-3377. PubMed ID: 33512452
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemotherapy enriches for an invasive triple-negative breast tumor cell subpopulation expressing a precursor form of N-cadherin on the cell surface.
    Nelson ER; Li S; Kennedy M; Payne S; Kilibarda K; Groth J; Bowie M; Parilla-Castellar E; de Ridder G; Marcom PK; Lyes M; Peterson BL; Cook M; Pizzo SV; McDonnell DP; Bachelder RE
    Oncotarget; 2016 Dec; 7(51):84030-84042. PubMed ID: 27768598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2.
    Nicoletti R; Lopez S; Bellone S; Cocco E; Schwab CL; Black JD; Centritto F; Zhu L; Bonazzoli E; Buza N; Hui P; Mezzanzanica D; Canevari S; Schwartz PE; Rutherford TJ; Santin AD
    Clin Exp Metastasis; 2015 Jan; 32(1):29-38. PubMed ID: 25398397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.